Kinase inhibitor combinations for cancer treatment
Номер патента: EP4243819A1
Опубликовано: 20-09-2023
Автор(ы): Anderson CLARK, Andreas Machl, Bayard Huck, Erik WILKER, Remigiusz KALETA
Принадлежит: Merck Patent GmBH
Опубликовано: 20-09-2023
Автор(ы): Anderson CLARK, Andreas Machl, Bayard Huck, Erik WILKER, Remigiusz KALETA
Принадлежит: Merck Patent GmBH
Реферат: The invention relates to combinations of 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide and/or its physiologically acceptable salts and solvates, and an inhibitor of MEK kinase, and as an optional third inhibitor, with an inhibitor of EGFR, and the use of such combinations for the treatment of cancer, and to combinations of 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide and/or its physiologically acceptable salts and solvates, and an inhibitor of EGFR.
Combination of cd19 antibody and bruton tyrosine kinase inhibitor and their application
Номер патента: RU2756010C2. Автор: Ян ЭНДЕЛЛЬ,Райнер БОКСХАММЕР,Марк ВИНДЕРЛИХ. Владелец: МорфоСис АГ. Дата публикации: 2021-09-24.